Co-occurrence of interstitial lung disease and pulmonary embolism as adverse events of adjuvant osimertinib treatment for EGFR mutant non-small cell lung cancer: a case report
Abstract Background Postoperative osimertinib for EGFR mutant non-small cell lung cancer has become the standard of care. However, its adverse events in clinical practice remain unclear. We report a case of interstitial lung disease and pulmonary embolism occurring simultaneously as adverse events d...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-025-03787-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849238815959416832 |
|---|---|
| author | Kenta Manabe Kazuhiko Shien Shinichi Furukawa Tomoya Seno Kousei Ishimura Shin Tanaka Ken Suzawa Mikio Okazaki Seiichiro Sugimoto Shinichi Toyooka |
| author_facet | Kenta Manabe Kazuhiko Shien Shinichi Furukawa Tomoya Seno Kousei Ishimura Shin Tanaka Ken Suzawa Mikio Okazaki Seiichiro Sugimoto Shinichi Toyooka |
| author_sort | Kenta Manabe |
| collection | DOAJ |
| description | Abstract Background Postoperative osimertinib for EGFR mutant non-small cell lung cancer has become the standard of care. However, its adverse events in clinical practice remain unclear. We report a case of interstitial lung disease and pulmonary embolism occurring simultaneously as adverse events during adjuvant osimertinib treatment. Case presentation A 74-year-old woman, diagnosed with left lower lobe lung adenocarcinoma harboring an EGFR mutation, underwent a left lower lobectomy with lymph node dissection. During adjuvant osimertinib therapy, the patient developed respiratory distress with hypoxia, leading to the diagnosis of interstitial lung disease. Despite immediate steroid therapy, respiratory distress persisted, the patient developed leg edema. She was diagnosed with deep vein thrombosis and pulmonary embolism via contrast-enhanced computed tomography scan. Following treatment with steroid and anticoagulation, her clinical symptoms improved rapidly, and she showed no recurrence of interstitial lung disease, pulmonary embolism, or lung cancer over the following nine months. Conclusions We encountered a case of interstitial lung disease and pulmonary embolism occurring simultaneously as adverse events during adjuvant osimertinib treatment. In patients with osimertinib-induced interstitial lung disease, particularly when respiratory symptoms show poor improvement with steroid treatment, the possibility of pulmonary embolism complications should be suspected. |
| format | Article |
| id | doaj-art-0503a88aaba044bda16da49aa09e8cd0 |
| institution | Kabale University |
| issn | 1471-2466 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj-art-0503a88aaba044bda16da49aa09e8cd02025-08-20T04:01:24ZengBMCBMC Pulmonary Medicine1471-24662025-07-012511510.1186/s12890-025-03787-7Co-occurrence of interstitial lung disease and pulmonary embolism as adverse events of adjuvant osimertinib treatment for EGFR mutant non-small cell lung cancer: a case reportKenta Manabe0Kazuhiko Shien1Shinichi Furukawa2Tomoya Seno3Kousei Ishimura4Shin Tanaka5Ken Suzawa6Mikio Okazaki7Seiichiro Sugimoto8Shinichi Toyooka9Department of Thoracic Surgery, Okayama University HospitalDepartment of Thoracic Surgery, Okayama University HospitalDepartment of Thoracic Surgery, Okayama University HospitalDepartment of Thoracic Surgery, Okayama University HospitalDepartment of Thoracic Surgery, Okayama University HospitalDepartment of Thoracic Surgery, Okayama University HospitalDepartment of Thoracic Surgery, Okayama University HospitalDepartment of Thoracic Surgery, Okayama University HospitalDepartment of Thoracic Surgery, Okayama University HospitalDepartment of Thoracic Surgery, Okayama University HospitalAbstract Background Postoperative osimertinib for EGFR mutant non-small cell lung cancer has become the standard of care. However, its adverse events in clinical practice remain unclear. We report a case of interstitial lung disease and pulmonary embolism occurring simultaneously as adverse events during adjuvant osimertinib treatment. Case presentation A 74-year-old woman, diagnosed with left lower lobe lung adenocarcinoma harboring an EGFR mutation, underwent a left lower lobectomy with lymph node dissection. During adjuvant osimertinib therapy, the patient developed respiratory distress with hypoxia, leading to the diagnosis of interstitial lung disease. Despite immediate steroid therapy, respiratory distress persisted, the patient developed leg edema. She was diagnosed with deep vein thrombosis and pulmonary embolism via contrast-enhanced computed tomography scan. Following treatment with steroid and anticoagulation, her clinical symptoms improved rapidly, and she showed no recurrence of interstitial lung disease, pulmonary embolism, or lung cancer over the following nine months. Conclusions We encountered a case of interstitial lung disease and pulmonary embolism occurring simultaneously as adverse events during adjuvant osimertinib treatment. In patients with osimertinib-induced interstitial lung disease, particularly when respiratory symptoms show poor improvement with steroid treatment, the possibility of pulmonary embolism complications should be suspected.https://doi.org/10.1186/s12890-025-03787-7OsimertinibLung cancerInterstitial lung diseasePulmonary embolism |
| spellingShingle | Kenta Manabe Kazuhiko Shien Shinichi Furukawa Tomoya Seno Kousei Ishimura Shin Tanaka Ken Suzawa Mikio Okazaki Seiichiro Sugimoto Shinichi Toyooka Co-occurrence of interstitial lung disease and pulmonary embolism as adverse events of adjuvant osimertinib treatment for EGFR mutant non-small cell lung cancer: a case report BMC Pulmonary Medicine Osimertinib Lung cancer Interstitial lung disease Pulmonary embolism |
| title | Co-occurrence of interstitial lung disease and pulmonary embolism as adverse events of adjuvant osimertinib treatment for EGFR mutant non-small cell lung cancer: a case report |
| title_full | Co-occurrence of interstitial lung disease and pulmonary embolism as adverse events of adjuvant osimertinib treatment for EGFR mutant non-small cell lung cancer: a case report |
| title_fullStr | Co-occurrence of interstitial lung disease and pulmonary embolism as adverse events of adjuvant osimertinib treatment for EGFR mutant non-small cell lung cancer: a case report |
| title_full_unstemmed | Co-occurrence of interstitial lung disease and pulmonary embolism as adverse events of adjuvant osimertinib treatment for EGFR mutant non-small cell lung cancer: a case report |
| title_short | Co-occurrence of interstitial lung disease and pulmonary embolism as adverse events of adjuvant osimertinib treatment for EGFR mutant non-small cell lung cancer: a case report |
| title_sort | co occurrence of interstitial lung disease and pulmonary embolism as adverse events of adjuvant osimertinib treatment for egfr mutant non small cell lung cancer a case report |
| topic | Osimertinib Lung cancer Interstitial lung disease Pulmonary embolism |
| url | https://doi.org/10.1186/s12890-025-03787-7 |
| work_keys_str_mv | AT kentamanabe cooccurrenceofinterstitiallungdiseaseandpulmonaryembolismasadverseeventsofadjuvantosimertinibtreatmentforegfrmutantnonsmallcelllungcanceracasereport AT kazuhikoshien cooccurrenceofinterstitiallungdiseaseandpulmonaryembolismasadverseeventsofadjuvantosimertinibtreatmentforegfrmutantnonsmallcelllungcanceracasereport AT shinichifurukawa cooccurrenceofinterstitiallungdiseaseandpulmonaryembolismasadverseeventsofadjuvantosimertinibtreatmentforegfrmutantnonsmallcelllungcanceracasereport AT tomoyaseno cooccurrenceofinterstitiallungdiseaseandpulmonaryembolismasadverseeventsofadjuvantosimertinibtreatmentforegfrmutantnonsmallcelllungcanceracasereport AT kouseiishimura cooccurrenceofinterstitiallungdiseaseandpulmonaryembolismasadverseeventsofadjuvantosimertinibtreatmentforegfrmutantnonsmallcelllungcanceracasereport AT shintanaka cooccurrenceofinterstitiallungdiseaseandpulmonaryembolismasadverseeventsofadjuvantosimertinibtreatmentforegfrmutantnonsmallcelllungcanceracasereport AT kensuzawa cooccurrenceofinterstitiallungdiseaseandpulmonaryembolismasadverseeventsofadjuvantosimertinibtreatmentforegfrmutantnonsmallcelllungcanceracasereport AT mikiookazaki cooccurrenceofinterstitiallungdiseaseandpulmonaryembolismasadverseeventsofadjuvantosimertinibtreatmentforegfrmutantnonsmallcelllungcanceracasereport AT seiichirosugimoto cooccurrenceofinterstitiallungdiseaseandpulmonaryembolismasadverseeventsofadjuvantosimertinibtreatmentforegfrmutantnonsmallcelllungcanceracasereport AT shinichitoyooka cooccurrenceofinterstitiallungdiseaseandpulmonaryembolismasadverseeventsofadjuvantosimertinibtreatmentforegfrmutantnonsmallcelllungcanceracasereport |